Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age - Top-Institutions - MDSpire

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age

  • By

  • Abdi Naficy

  • Mireille Venken

  • Yingmei Xi

  • Mark Loughrey

  • Giulietta Maruggi

  • Hema Sharma

  • Kunal Aggarwal

  • Daniel Brune

  • Bach-Yen Nguyen

  • November 26, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Vaccine Research

  • #2

    Vaccine Research Center (VRC), NIAID, NIH
    Vaccine Research Center (VRC), NIAID, NIH

    Bethesda, MD

    Key Differentiators

    • Vaccine Development
    • Immunology
    • Clinical Trials

  • #3

    Johns Hopkins Bloomberg School of Public Health
    Johns Hopkins Bloomberg School of Public Health

    Baltimore, MD

    Key Differentiators

    • Epidemiology
    • Infectious Diseases
    • Vaccine Trials

  • #4

    Massachusetts General Hospital (MGH) Vaccine and Immunotherapy Center
    Massachusetts General Hospital (MGH) Vaccine and Immunotherapy Center

    Boston, MA

    Key Differentiators

    • Immunology
    • Vaccine Development
    • Clinical Research

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Immunology
    • Gene Therapy
    • Vaccine Research

Original Source(s)

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age

  • by Abdi Naficy, Mireille Venken, Yingmei Xi, Mark Loughrey, Giulietta Maruggi, Hema Sharma, Kunal Aggarwal, Daniel Brune, Bach-Yen Nguyen

  • November 26, 2025

Related Content

Assessing PEPFAR’s Economic and Educational Spillover Effects: An Update

Immune remodeling and metabolic reprogramming in chronic fatigue: insights into GPCR signaling and epigenetic regulation

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min